Mobile van study of a long-acting HIV prevention shot
Treatments studied
Part of Infections clinical trials.
This study tests if giving a long-acting HIV prevention shot (lenacapavir) from a mobile medical van can reach people at risk for HIV in Los Angeles County. You may be able to join if you are HIV negative, at risk for HIV, and are willing to try a shot instead of a daily pill.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You speak English or Spanish.
- You are HIV negative (confirmed by a rapid test on the day you join).
- You are at risk for HIV (for example, you want PrEP or your clinician thinks you may benefit).
- You are willing to stop any other PrEP medication you are currently taking.
- You can be reached by a UCLA mobile health van in Los Angeles County.
- Pregnant or breastfeeding women can join after discussing risks and benefits with the doctor.
- Your BMI must be under 35 (about 77 pounds or less is not allowed).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study offers a long-acting injectable form of PrEP (lenacapavir) to prevent HIV in Latine transgender women and gay men in the South. It aims to make HIV prevention easier by providing a shot instead of a daily pill.
This study tests an all-in-one HIV prevention package for young men at higher risk of HIV. It combines a new long-acting PrEP (injectable HIV prevention) with mobile health support and sexually transmitted infection prevention. The goal is to see if this comprehensive approach works better than standard care.
This study looks at a long-acting injectable HIV prevention medication (called cabotegravir) to see how well it works in real life. If you are already taking or starting this shot, you may be able to join and help improve HIV prevention care.
This study tests a nurse-led program that offers a long-acting injectable medication (cabotegravir) to prevent HIV. The injection is given every two months, and the program aims to make it easier to access this prevention option at your local health center.
This trial tests a new medication, lenacapavir, to see how well it works for preventing HIV. It is for people who want or need PrEP (a medicine to prevent HIV) and are interested in learning about different options.
This study tests a new injectable medication called lenacapavir to prevent HIV infection. You get to choose between different HIV prevention options, and the study will see how well the injection works for you.
Hear when a new HIV Prevention trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.